Ascentage Pharma announced on June 15, 2025, that multiple studies reported encouraging data for its novel drug olverembatinib (HQP1351) at the 2025 European Hematology Association (EHA) Annual Congress. Olverembatinib demonstrated broad therapeutic potential, particularly in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Results showed high complete remission (CR) and complete molecular response (CMR) rates, along with favorable tolerability, in the first-line treatment of newly diagnosed and relapsed/refractory Ph+ ALL. Studies on various combinations of olverembatinib also yielded encouraging results.
These findings reinforce olverembatinib's clinical benefit and potential to offer more treatment options and improved long-term prognoses for patients with Ph+ ALL. Additionally, preclinical data for the investigational EED inhibitor APG-5918 in T-cell lymphoma were presented, showing potent antitumor activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.